New drug targets fatty liver in transplant patients

NCT ID NCT07335601

Recruiting now Disease control Sponsor: Madrigal Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jan 14, 2026 · Last updated Jun 19, 2026 · Updated 34 times

Summary

This study tests whether resmetirom, a daily pill, can reduce liver fat in people who have had a liver transplant and developed MASH (a type of fatty liver disease). About 120 participants will be randomly assigned to receive either resmetirom or a placebo for 28 weeks. The main goal is to see if the drug lowers liver fat as measured by MRI.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Dallas Methodist
RECRUITING

Dallas, Texas, 75203, United States
Houston Methodist Hospital
NOT_YET_RECRUITING

Houston, Texas, 77030, United States
Intermountain Medical Center
RECRUITING

Murray, Utah, 84107, United States
Mayo Clinic
NOT_YET_RECRUITING

Rochester, Minnesota, 55905, United States
Medstar Georgetown University Hospital
NOT_YET_RECRUITING

Washington D.C., District of Columbia, 20007, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
New York Presbyterian Hospital
NOT_YET_RECRUITING

New York, New York, 10065, United States
Northwell Health Inc, Center for Liver Disease and Transplantation
NOT_YET_RECRUITING

Manhasset, New York, 11030, United States
Northwestern University
RECRUITING

Chicago, Illinois, 60208, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
The University of Chicago Medicine
NOT_YET_RECRUITING

Chicago, Illinois, 60637, United States
University Health Network - Toronto General Hospital (TGH)
NOT_YET_RECRUITING

Toronto, Ontario, M5G 2C4, Canada
University of California Los Angeles Medical Center
NOT_YET_RECRUITING

Los Angeles, California, 90095, United States
University of California San Diego
NOT_YET_RECRUITING

La Jolla, California, 92037, United States
University of California, San Francisco
RECRUITING

San Francisco, California, 94143, United States
University of Colorado
NOT_YET_RECRUITING

Aurora, Colorado, 80045, United States
University of Nebraska
NOT_YET_RECRUITING

Omaha, Nebraska, 68198-2000, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
University of Virginia Health System
NOT_YET_RECRUITING

Charlottesville, Virginia, 22903, United States
Vanderbilt University Medical Center (VUMC)
RECRUITING

Nashville, Tennessee, 37212, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Resmetirom (MGL-3196)

What this could lead to

If successful, this could offer a treatment to reduce liver fat and prevent further liver damage in transplant patients with MASH.

What could go wrong

This is an early Phase 2 trial with only 120 participants. The drug may not work better than placebo, and side effects are still being studied.

Conditions

The condition(s) this trial relates to.

Fibrosis metabolic dysfunction-associated steatohepatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS